Volume 5.33 | Aug 22

Mammary Cell News 5.33 August 22, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
NAF-1 and mitoNEET Are Central to Human Breast Cancer Proliferation by Maintaining Mitochondrial Homeostasis and Promoting Tumor Growth
Scientists showed that the protein levels of nutrient-deprivation autophagy factor-1 (NAF-1) and mitoNEET are elevated in human epithelial breast cancer cells, and that suppression of these proteins using shRNA can result in significantly reduced cell proliferation and tumor growth, decreased mitochondrial performance, uncontrolled accumulation of iron and reactive oxygen in mitochondria, and activation of autophagy. [Proc Natl Acad Sci USA] Abstract | Press Release
Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by impact factor of the journal)

Developmental Changes in the In Vitro Activated Regenerative Activity of Primitive Mammary Epithelial Cells
Researchers showed that fetal mammary epithelial cells have a greater direct and inducible growth potential than their adult counterparts. The latter feature is revealed in a novel culture system that enables large numbers of in vitro clonogenic progenitors as well as mammary stem cells with serially transplantable activity to be produced within seven days from single fetal or adult input cells. [PLos Biol] Full Article

Hbo1 Is a Cyclin E/CDK2 Substrate that Enriches Breast Cancer Stem-Like Cells
To explore how low-molecular weight cyclin E enriches cancer stem cells in breast tumors, scientists conducted a protein microarray analysis that identified the histone acetyltransferase Hbo1 as a novel cyclin E/ cyclin-dependent kinase 2 (CDK2) substrate. [Cancer Res] Abstract

Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors
A multiscale systems model of signaling networks in ERBB2-amplified breast cancer was developed to quantitatively investigate relationships between biomarkers and combination drug efficacy, which linked ErbB receptor family signaling to breast tumor growth the PI3K/AKT survival pathway and the Ras/MEK/ERK growth and proliferation pathway. [Sci Signal] Abstract

Evidence for a Multipotent Mammary Progenitor with Pregnancy-Specific Activity
Researchers identified a population of mammary epithelial cells containing pregnancy-activated multipotent progenitors that are present in the virgin mammary gland and contribute to the expansion of the mammary gland during pregnancy. [Breast Cancer Res] Abstract | Full Article

Cancer Stemness in Wnt-Driven Mammary Tumorigenesis
By employing the CD24 and CD29 cell surface antigens, investigators have identified a subpopulation of mammary cancer stem cells from the endogenous Apc gene (Apc1572T/+) capable of self-renewal and differentiation both in vivo and in vitro. [Carcinogenesis] Abstract

The 18-kDa Translocator Protein (TSPO) Disrupts Mammary Epithelial Morphogenesis and Promotes Breast Cancer Cell Migration
Scientists demonstrated that stable overexpression of TSPO in mammary epithelial MCF10A acini drives proliferation and provides partial resistance to luminal apoptosis, resulting in enlarged acinar structures with partially filled lumen that resemble early stage breast lesions leading to breast cancer. [PLos One]
Full Article

Flotillin-2 Is Associated with Breast Cancer Progression and Poor Survival Outcomes
Investigators describe that Flotillin-2 was significantly upregulated in breast cancer cell lines and tissue samples compared with normal cells and adjacent noncancerous breast tissues, respectively. [J Transl Med]
Abstract | Full Article


HER2-Overexpressing Breast Cancer: FDG Uptake after Two Cycles of Chemotherapy Predicts the Outcome of Neoadjuvant Treatment
The authors elucidated that the level of residual 18F-fluorodeoxyglucose (FDG) uptake after two cycles of chemotherapy predicted residual disease at completion of neoadjuvant treatment with chemotherapy and trastuzumab with high accuracy. [Br J Cancer] Abstract

Predictive Value of Sphingosine Kinase 1 Expression in Neoadjuvant Treatment of Breast Cancer
Researchers studied the expression of Sphingosine Kinase 1 by immunohistochemistry, using tissue microarrays of pre-treatment core cut biopsies from 112 breast cancer specimens obtained from a prospective neoadjuvent chemotherapy trial. [J Cancer Res Clin Oncol] Abstract

Outcome of Patients with HER2-Positive Breast Cancer Treated with or without Adjuvant Trastuzumab in the Finland Capecitabine Trial (FinXX)
Investigators studied the outcomes of 284 patients with HER2-positive cancer, treated with adjuvant capecitabine-containing chemotherapy with or without trastuzumab. The primary endpoint was recurrence-free survival. [Acta Oncol] Full Article

Use Aldefluor to Detect Breast Cancer Stem Cells - Click here to learn more
Opportunities and Hurdles in the Treatment of BRCA1-Related Breast Cancer
Authors review the role of BRCA1 in both hereditary and sporadic breast cancer and discuss how different functionalities of the BRCA1 protein can contribute to its tumor suppressor function. [Oncogene] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Mayo Clinic Center for Individualized Medicine Helps Treat Complex Cancers, Solve Medical Mysteries
To help Mayo Clinic physicians and researchers usher in a new age of medicine that uses technologies like whole genome sequencing to find solutions for patients, Cecilia and Dan Carmichael have donated $5 million to Mayo. [Mayo Foundation for Medical Education and Research] Press Release

Fighting Breast Cancer with Immunotherapy
Supported by a National Breast Cancer Foundation Fellowship, Dr Trina Stewart has applied for a $750,000 National Health and Medical Research Council grant which will enable her to extend her work to pre-clinical models of human breast cancer stem cells. [Griffith University] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Frontiers in Cancer Science 2013
November 5-7, 2013
Singapore, Singapore

NEW Australian Breast Cancer Conference 2013
November 7-8, 2013
Melbourne, Australia

Visit our events page to see a complete list of events in the mammary cell community.
NEW Tenure-Track Position – Cell Biologist (McGill University)

NEW PhD Studentship – c-Met Pathway in Trastuzumab Resistant Breast Cancer (Barts Cancer Institute, Queen Mary University of London)

NEW Postdoctoral Fellow in Breast Cancer – (Bellvitge Biomedical Research Institute [IDIBELL])

Faculty Position – Detection and Diagnosis of Solid Tumors (Stanford University)

Postdoctoral Fellow – Breast Cancer Cell Research (Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Mammary Cell News: Archives | Events | Contact Us